Biologics and Psoriasis: The Beat Goes On

Hee J. Kim; Mark G. Lebwohl

doi:10.1016/j.det.2018.07.004

Biologics and Psoriasis: The Beat Goes On

Hee J. Kim
, Mark G. Lebwohl

Research output: Contribution to journal › Review article › peer-review

52 Scopus citations

Abstract

Psoriasis is a chronic, immune-mediated, inflammatory skin disease that requires long-term therapy for disease control. This article reviews data presented in clinical trials to evaluate and compare various characteristics of biologics that are currently approved for the treatment of psoriasis. Attributes of biological agents that are examined in this article include efficacy, long-term maintenance, overall safety, median time to onset of efficacy, adjustment for body weight, frequency of injections, indication for psoriatic arthritis, and safety in pregnancy. Here, we evaluate what the ideal choice of biological therapy may be for psoriasis patients with specific needs.

Original language	English
Pages (from-to)	29-36
Number of pages	8
Journal	Dermatologic Clinics
Volume	37
Issue number	1
DOIs	https://doi.org/10.1016/j.det.2018.07.004
State	Published - Jan 2019

Keywords

Biologics
Efficacy
Psoriasis
Psoriatic arthritis
Safety
Th17/IL-23 axis

Access to Document

10.1016/j.det.2018.07.004

Cite this

@article{ab0850039b5746b19201a99040e74746,

title = "Biologics and Psoriasis: The Beat Goes On",

abstract = "Psoriasis is a chronic, immune-mediated, inflammatory skin disease that requires long-term therapy for disease control. This article reviews data presented in clinical trials to evaluate and compare various characteristics of biologics that are currently approved for the treatment of psoriasis. Attributes of biological agents that are examined in this article include efficacy, long-term maintenance, overall safety, median time to onset of efficacy, adjustment for body weight, frequency of injections, indication for psoriatic arthritis, and safety in pregnancy. Here, we evaluate what the ideal choice of biological therapy may be for psoriasis patients with specific needs.",

keywords = "Biologics, Efficacy, Psoriasis, Psoriatic arthritis, Safety, Th17/IL-23 axis",

author = "Kim, \{Hee J.\} and Lebwohl, \{Mark G.\}",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2019",

month = jan,

doi = "10.1016/j.det.2018.07.004",

language = "English",

volume = "37",

pages = "29--36",

journal = "Dermatologic Clinics",

issn = "0733-8635",

publisher = "W.B. Saunders",

number = "1",

}

TY - JOUR

T1 - Biologics and Psoriasis

T2 - The Beat Goes On

AU - Kim, Hee J.

AU - Lebwohl, Mark G.

PY - 2019/1

Y1 - 2019/1

N2 - Psoriasis is a chronic, immune-mediated, inflammatory skin disease that requires long-term therapy for disease control. This article reviews data presented in clinical trials to evaluate and compare various characteristics of biologics that are currently approved for the treatment of psoriasis. Attributes of biological agents that are examined in this article include efficacy, long-term maintenance, overall safety, median time to onset of efficacy, adjustment for body weight, frequency of injections, indication for psoriatic arthritis, and safety in pregnancy. Here, we evaluate what the ideal choice of biological therapy may be for psoriasis patients with specific needs.

AB - Psoriasis is a chronic, immune-mediated, inflammatory skin disease that requires long-term therapy for disease control. This article reviews data presented in clinical trials to evaluate and compare various characteristics of biologics that are currently approved for the treatment of psoriasis. Attributes of biological agents that are examined in this article include efficacy, long-term maintenance, overall safety, median time to onset of efficacy, adjustment for body weight, frequency of injections, indication for psoriatic arthritis, and safety in pregnancy. Here, we evaluate what the ideal choice of biological therapy may be for psoriasis patients with specific needs.

KW - Biologics

KW - Efficacy

KW - Psoriasis

KW - Psoriatic arthritis

KW - Safety

KW - Th17/IL-23 axis

UR - https://www.scopus.com/pages/publications/85055738896

U2 - 10.1016/j.det.2018.07.004

DO - 10.1016/j.det.2018.07.004

M3 - Review article

C2 - 30466686

AN - SCOPUS:85055738896

SN - 0733-8635

VL - 37

SP - 29

EP - 36

JO - Dermatologic Clinics

JF - Dermatologic Clinics

IS - 1

ER -

Biologics and Psoriasis: The Beat Goes On

Abstract

Keywords

Access to Document

Fingerprint

Cite this